Insmed Inc INSM
We take great care to ensure that the data presented and summarized in this overview for INSMED Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding INSM
View all-
Jpmorgan Chase & CO New York, NY23MShares$4.45 Billion0.22% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y920.5MShares$3.95 Billion89.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.9MShares$3.85 Billion0.04% of portfolio
-
Black Rock Inc. New York, NY14.3MShares$2.76 Billion0.02% of portfolio
-
Capital International Investors Los Angeles, CA7.55MShares$1.46 Billion0.18% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.93MShares$1.34 Billion0.11% of portfolio
-
Baker Bros. Advisors LP New York, NY6.7MShares$1.3 Billion7.86% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY5.66MShares$1.09 Billion0.52% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.94MShares$954 Million1.09% of portfolio
-
State Street Corp Boston, MA3.98MShares$770 Million0.02% of portfolio
Latest Institutional Activity in INSM
Top Purchases
Top Sells
About INSM
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Insider Transactions at INSM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 08
2026
|
William Lewis Chair and CEO |
SELL
Open market or private sale
|
Direct |
3,223
-1.01%
|
$560,802
$174.17 P/Share
|
|
Jan 08
2026
|
Martina M.D. Flammer Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,911
-2.71%
|
$854,514
$174.02 P/Share
|
|
Jan 08
2026
|
Sara Bonstein Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,447
-1.77%
|
$251,778
$174.17 P/Share
|
|
Jan 08
2026
|
Roger Adsett Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,059
-1.88%
|
$358,266
$174.17 P/Share
|
|
Jan 08
2026
|
Michael Alexander Smith Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,053
-1.81%
|
$183,222
$174.17 P/Share
|
|
Jan 07
2026
|
William Lewis Chair and CEO |
SELL
Open market or private sale
|
Direct |
2,357
-0.73%
|
$412,475
$175.07 P/Share
|
|
Jan 07
2026
|
Martina M.D. Flammer Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,434
-1.54%
|
$250,950
$175.84 P/Share
|
|
Jan 07
2026
|
Sara Bonstein Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,678
-2.01%
|
$293,650
$175.07 P/Share
|
|
Jan 07
2026
|
Roger Adsett Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
802
-0.73%
|
$140,350
$175.07 P/Share
|
|
Jan 07
2026
|
Michael Alexander Smith Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
709
-1.21%
|
$124,075
$175.07 P/Share
|
|
Jan 06
2026
|
William Lewis Chair and CEO |
SELL
Open market or private sale
|
Direct |
4,096
-1.26%
|
$708,608
$173.33 P/Share
|
|
Jan 06
2026
|
Martina M.D. Flammer Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,185
-2.55%
|
$1,772,190
$174.01 P/Share
|
|
Jan 06
2026
|
Martina M.D. Flammer Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,570
+7.66%
|
$222,820
$26.43 P/Share
|
|
Jan 06
2026
|
Sara Bonstein Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,517
-1.78%
|
$262,441
$173.33 P/Share
|
|
Jan 06
2026
|
Roger Adsett Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,429
-1.28%
|
$247,217
$173.33 P/Share
|
|
Jan 06
2026
|
Michael Alexander Smith Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,396
-2.32%
|
$241,508
$173.33 P/Share
|
|
Jan 05
2026
|
Martina M.D. Flammer Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,303
-1.72%
|
$2,116,116
$172.35 P/Share
|
|
Jan 05
2026
|
Martina M.D. Flammer Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,303
+5.56%
|
$295,272
$24.43 P/Share
|
|
Jan 02
2026
|
Michael Alexander Smith Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,293
+8.08%
|
-
|
|
Jan 02
2026
|
Roger Adsett Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,998
+5.09%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 638K shares |
|---|---|
| Exercise of conversion of derivative security | 1.25M shares |
| Bona fide gift | 67.6K shares |
| Open market or private purchase | 3.03K shares |
| Open market or private sale | 2.09M shares |
|---|---|
| Bona fide gift | 109K shares |